Hepatitis C in Children

Rumbo, Carolina; Fawaz, Rima; Emre, Sükrü; Suchy, Frederick J.; Kerkar, Nanda; Morotti, Raffaella; Shneider, Benjamin L.

doi:10.1097/01.mpg.0000228117.52229.32

Cited by 72 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Complications from chronic HCV‐related liver disease in children and adolescents, such as portal hypertension, ascites, variceal bleeding, and hepatocellular carcinoma, although uncommon, have been reported 2, 73, 89, 90, 91. Decompensated cirrhosis in children as young as 4 years of age has been described 48, 78, 91, 92.…”

Section: Natural History Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

“…Decompensated cirrhosis in children as young as 4 years of age has been described 48, 78, 91, 92. HCV infection in children has also been suggested to negatively affect both health‐related quality of life and cognitive functioning; however, these findings would need to be confirmed in larger cohorts 93, 94…”

Section: Natural History Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus infection in children and adolescents

Squires

Balistreri

2017

Hepatology Communications

View full text Add to dashboard Cite

Section: Natural History Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

Section: Natural History Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

Hepatitis C virus infection in children and adolescents

Squires

Balistreri

2017

Hepatology Communications

View full text Add to dashboard Cite

“…On the other hand, adolescents who become infected follow the adult pattern of disease 2. However, CHC is considered a progressive disease with accumulating liver damage:17 there is a 26-fold increase in risk of liver-related death associated with CHC acquired in childhood;11 bridging fibrosis is reportedly present in 12% of children;18 cirrhosis is present in 1–2% of children; decompensated cirrhosis has been documented in children between the ages of 4–11; and liver transplantation may be necessary for end-stage liver disease secondary to CHC 16. Furthermore, hepatocellular carcinoma has been reported in adults with CHC in the absence of cirrhosis 19…”

Section: Natural History Of Hcv In Childrenmentioning

confidence: 99%

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C

Yang

Yoo

Ahmed

2017

JCTH

View full text Add to dashboard Cite

In the United States, chronic infection with the hepatitis C virus (HCV) affects an estimated 0.1-2% of the pediatric population, who are consequently at risk for major complications, including cirrhosis, hepatocellular carcinoma, and death. The current standard of treatment for chronic hepatitis C (CHC) in children is pegylated-interferon-alpha (PEG-IFN) in combination with ribavirin. PEG-IFN/ribavirin therapy is approved for children ages 3 and older; however, it is often held from use until adulthood because of its extensive list of potential side effects and high likelihood of causing adverse symptoms. While CHC is usually indolent in children and adolescents, immediately treating and curbing the spread of HCV before adulthood is important, as there can be transmission to other individuals via sexual activity and infected females can later vertically transmit the infection during pregnancy, the latter representing the most common means of transmission for children in the United States. The recent development of direct-acting antivirals has shown promising results in clinical trials for use in children and has dramatically increased the rates of sustained virological response in adults while improving side effect profiles as compared to interferonbased treatments. Given the usually indolent course of CHC in children, significant side effects of the currently-approved PEG-IFN/ribavirin therapy, and likely availability of all-oral interferon-free regimens for children within a few years, deferring treatment in clinically-stable children with CHC in anticipation of upcoming superior treatment modalities may be justified. Citation of this article: Yang CHT, Yoo ER, Ahmed A. The role of direct-acting antivirals in the treatment of children with chronic hepatitis C.

show abstract

“…Few studies are available on the combined treatment with subcutaneous peginterferon-á-2a or peginterferon-á-2b and oral ribavirin in children with chronic hepatitis C 54,72–79. In this review, we examine the results of seven studies on the combined treatment.…”

Section: Combined Treatment With Peginterferon-á and Ribavirinmentioning

confidence: 99%

“…The second is a retrospective, multicenter, collaborative study by the Japan Society of Pediatric Hepatology on 33 children and young adults 78. Two more studies on combined treatment have been published, but were excluded from the analysis performed in this review, in one case because it was not possible to extrapolate the children treated with peginterferon-á-2a and those treated with peginterferon-á-2b79 and the other because the patients enrolled were on treatment at the end of the follow-up 54…”

Section: Combined Treatment With Peginterferon-á and Ribavirinmentioning

confidence: 99%

Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy

Indolfi

Bartolini

Casavola

et al. 2010

AHMT

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is the most common cause of chronic liver disease of infectious etiology in children. Most of the children infected with HCV are asymptomatic, and only a few of them develop signs and symptoms of end-stage liver disease early in life. It is not possible to predict either in which patients HCV infection will have a bad outcome or the critical time in early adulthood when disease progression will accelerate. The experiences with therapy in children with chronic hepatitis C are based on earlier and continuing data from adult trials. The currently recommended treatment for chronic HCV infection in adults is the combination of peginterferon-á and ribavirin. The choice of this regimen is based on the results of randomized clinical trials that demonstrated the superiority of this combination treatment over standard interferon-á and ribavirin. Recently, results of pivotal, multicenter, interventional open-label studies on combined treatment with peginterferon-á and ribavirin in children have been published, and the US Food and Drug Administration and the European Medicines Agency have approved the combination therapy in those older than 3 years. The aim of this review is to evaluate critically the available data regarding the safety and efficacy of combination treatment with peginterferon-á and ribavirin in children.

show abstract

Hepatitis C in Children

Cited by 72 publications

References 44 publications

Hepatitis C virus infection in children and adolescents

Hepatitis C virus infection in children and adolescents

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C

Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy

Contact Info

Product

Resources

About